Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects
- Conditions
- Healthy adult male
- Registration Number
- JPRN-jRCT2080223296
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Brief Summary
The GMRs for brexpiprazole Cmax, AUCt and AUC of 4-mg brexpiprazole ODT with/without water to 4-mg brexpiprazole conventional tablet were around 1.0, and their 90% CI were within the 0.80 - 1.25 bioequivalence range. Brexpiprazole was safe and well tolerated in brexpirazole ODT with water, brexpirpazole ODT without water and brexpirpazole conventional tablet with no clinically significant differences between the ODT and conventional tablet formulations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- Male
- Target Recruitment
- 18
Capable of providing written informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all requirements of the trial
- Clinically significant abnormality at the time of screening (eg, significant deviation from reference ranges) or in medical history that, in the opinion of investigator or sponsor may place the subject at risk or interfere with outcome variables, including drug absorption, distribution, metabolism, and excretion
- History of serious mental disorder
- History of drug or alcohol abuse within 2 years prior to screening
- History of any significant drug allergy
- Use of an investigational drug within 120 days prior to the first dosing of trial drug
- Use of tobacco products or daily exposure to secondhand smoke within 2 months prior to screening
- Consumption of grapefruit, grapefruit products, Seville oranges, Seville orange products, starfruit, or starfruit products within 72 hours prior to dosing
- Use of prescription, over-the-counter, or herbal medication, vitamin supplements, or St. John's Wort within 14 days prior to the first dosing of trial drug, or of antibiotics within 30 days prior to the first dosing of trial drug
- History of major surgery of the digestive tract (excluding appendectomy)
- Any subject who, in the opinion of the investigator, should not participate in the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method